The results of these studies confirm that insulin resistance in genotype 1-HCV patients is the result of a more complex pathogenetic interrelation that is only marginally influenced by the activation of the proliferator-activated receptor-γ (PPAR-γ) pathway or via the metformin-induced hepatic AMP-activated protein kinase. Here, PPARG is linked to Insulin resistance.